达格列净对不同体重指数2型糖尿病患者血脂的影响

Effect of Dapagliflozin Treatment on Blood Lipid in Patients with Type 2 Diabetes Mellitus with Different Body Mass Indexes

目的:对不同体重指数(BMI)2型糖尿病患者服用钠-葡萄糖协同转运蛋白2抑制剂达格列净前后血脂及一般临床指标比较,评估其治疗作用。方法:选取2019年8月-2021年6月门诊治疗的2型糖尿病患者61例,依据BMI将其分为BMI正常组、超重组及肥胖组。三组患者均在原降糖方案的基础上加用达格列净。观察治疗前,治疗后12周及24周时,血脂及一般临床指标的变化。结果:BMI正常组患者治疗后12周的体重、BMI低于治疗前;治疗后24周的体重、BMI、腰围、甘油三酯、胆固醇、低密度脂蛋白低于治疗前,差异均有统计学意义(P<0.05)。超重组患者治疗后12周的低密度脂蛋白低于治疗前;治疗后24周的体重、BMI、腰围、总胆固醇、低密度脂蛋白低于治疗前,差异均有统计学意义(P<0.05)。肥胖组患者治疗后12周的体重、腰围、BMI低于治疗前;治疗后24周的体重、腰围、BMI低于治疗前,差异均有统计学意义(P<0.05)。结论:达格列净的降体重作用与基线体重无关,且减重的效果随着应用达格列净时间的延长而更为明显。达格列净亦可降低血脂。

Objective:To compare blood lipid and general clinical data before and after the treatment of sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes patients with different body mass index(BMI)and to evaluate the therapeutic effect.Methods:Sixty-one patients with type 2 diabetes treated in the outpatient department from August 2019 to June 2021 were selected in this study.According to BMI,the patients were divided into normal BMI group,overweight group,and obesity group.On the basis of the original hypoglycemic regimen,dapagliflozin was added to observe the changes in blood lipid and general clinical indicators before treatment,12 and 24 weeks after treatment.Results:Body weight and BMI in the normal BMI group were lower at 12 weeks after treatment than those before treatment.At 24 weeks after treatment,body weight,BMI,waist circumference,triglyceride,cholesterol,and low density lipoprotein were lower than those before treatment,with statistically significant difference(P<0.05).Low density lipoprotein in the overweight group was lower at 12 weeks after treatment than that before treatment.At 24 weeks after treatment,body weight,BMI,waist circumference,total cholesterol,and low density lipoprotein were lower than those before treatment,with statistically significant difference(P<0.05).The weight,waist circumference,and BMI of the obesity group were lower at 12 weeks after treatment than those before treatment.At 24 weeks after treatment,body weight,waist circumference,and BMI were lower than those before treatment,with statistically significant difference(P<0.05).Conclusion:It is suggested that the weight loss effect of dapagliflozin is independent of baseline body weight.The weight loss effect becomes more obvious with the prolonged time of dapagliflozin application.Dapagliflozin can also reduce blood lipid.